EverHint — Pullback Plays (with Insider, Earnings & News Overlays) - November 10, 2025
November 10, 2025
What this signal is (quick)
“Pullback Plays” hunts for stocks in established uptrends that dip to support and bounce (think 10–21–50 day trend zone, prior swing lows, or rising moving averages). The idea: buy strength-on-sale—enter on a constructive reaction after a controlled pullback, not on stretched highs. It’s momentum-friendly but avoids chasing.
Today’s candidates use end-of-day data for November 10, 2025 and this scanner remains experimental while we refine performance tracking.
How we ranked today (reader version)
Trend posture: sustained uptrend with a constructive dip-and-bounce.
Overlays: insider net flows (open-market buys − sales, last 90 days), days-to-earnings, and 30-day analyst-update cadence.
Headlines: most recent corporate news to confirm or challenge the move.
Note: Signals are for educational use and back-testing. We’ll keep tuning signal weights as live data accrues.
📈 Buy-Side Candidates — Pullback Plays
| # | Ticker | Company | Sector | Last ($) | % of 52-W High | Volume Thrust | Insider Net (USD, 90d) | Days → Earnings | Analyst Updates (30d) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NAMS | NewAmsterdam Pharma Company N.V. | Healthcare | 38.97 | 96.34% | 1.76 | −3,157,486 | — | 8 |
| 2 | PLTR | Palantir Technologies Inc. | Technology | 193.61 | 93.45% | 1.60 | −9,289,967 | 84 | 8 |
| 3 | COGT | Cogent Biosciences, Inc. | Healthcare | 32.46 | 100.00% | 6.95 | 0 | — | 10 |
Field notes
• Insider Net (USD) = open-market purchases − sales over the last 90 days (excludes awards/exercises).
• Days → Earnings = distance to next known report from today.
• Analyst Updates (30d) = count of estimate rows fetched in the last 30 days (proxy for recent sell-side attention).
Recent Headlines (confirmation/contradiction)
COGT — Cogent Biosciences
• Positive PEAK Phase 3 data in second-line GIST (bezuclastinib + sunitinib) showed 16.5-month median PFS vs. 9.2 months for sunitinib alone; shares surged triple-digits. (GlobeNewswire)
• Company filed concurrent offerings (convertible notes due 2031 and common stock). (GlobeNewswire)
PLTR — Palantir
• PLTR led today’s AI-tech rebound as broader markets rallied. (Reuters)
• Context: last week’s post-earnings valuation reset after a steep multi-month run. (MarketWatch)
NAMS — NewAmsterdam Pharma
• Q3 update released November 5; subsequent inducement grants disclosed November 7. (ir.newamsterdampharma.com)
• Coverage snippets noted volatility and revenue trajectory discussion. (Yahoo Finance)
Further reading on today’s big mover (COGT)
Carlo’s Take (EverHint)
Positioning: Today’s pullbacks lean Healthcare-heavy (COGT, NAMS) with PLTR offering a large-cap momentum dip inside the AI complex. COGT’s catalyst-driven spike means it’s no longer a “gentle pullback”—if trading it, I’d only add on orderly post-news basing. PLTR remains strong but watch the recent valuation noise; I prefer tiered entries on closes that hold above the 10–21 day zone for 2–3 sessions. For risk, anchor stops near prior swing lows instead of fixed moving averages.
Rotation snapshot: AI-adjacent mega-cap tech rebounded; biotech dominated single-name movers on clinical catalysts.
Independent research. No hype, no pumps, no paid promotions — just clean, data-driven signals and concise context.